Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery And/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial

Overview

Journal Pharmacoecon Open

Date 2022 May 5

PMID 35513735

Authors

Anh Dam Tran

Angela M Hong

Mai T H Nguyen

Gerald Fogarty

Victoria Steel

Elizabeth Paton

Rachael L Morton

Affiliations

Soon will be listed here.

Abstract

Purpose: We aimed to compare Australian health system costs at 12 months for adjuvant whole-brain radiotherapy (WBRT) treatment after stereotactic radiosurgery (SRS) and/or surgery versus observation among adults with one to three melanoma brain metastases. We hypothesized that treatment with adjuvant WBRT and subsequent healthcare would be more expensive than SRS/surgery alone.

Methods: The analysis was conducted alongside a multicentre, randomized phase III trial. A bespoke cost questionnaire was used to measure healthcare use, including hospitalizations, specialist and primary care visits, imaging, and medicines over 12 months. Mean per-patient costs were calculated based on the quantity of resources used and unit costs, reported in Australian dollars ($AU), year 2018 values. Skewness of cost data was determined using normality tests and censor-adjusted costs reported using the Kaplan-Meier sample average method. The analysis of difference in mean costs at each 2-month time point and at 12 months was performed and checked using Kruskal-Wallis, generalized linear models with gamma distribution and log link, modified Park test, ordinary least squares, and non-parametric bootstrapping.

Results: In total, 89 patients with similar characteristics at baseline were included in the cost analysis (n = 43 WBRT; n = 46 observation). Hospitalization cost was the main cost, ranging from 63 to 89% of total healthcare costs. The unadjusted 12-monthly cost for WBRT was $AU71,138 ± standard deviation 41,475 and for observation $AU69,848 ± 33,233; p = 0.7426. The censor-adjusted 12-monthly cost for WBRT was $AU90,277 ± 36,274 and $AU82,080 ± 34,411 for observation. There was no significant difference in 2-monthly costs between groups (p > 0.30 for all models).

Conclusions: Most costs were related to inpatient hospitalizations associated with disease recurrence. Adding WBRT after local SRS/surgery for patients with one to three melanoma brain metastases did not significantly increase health system costs during the first 12 months.

Trial Registration: ACTRN12607000512426, prospectively registered 14 September 2007.

References

Mooney M, Mettlin C, Michalek A, Petrelli N, Kraybill W . Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer. 1997; 80(6):1052-64. DOI: 10.1002/(sici)1097-0142(19970915)80:6<1052::aid-cncr7>3.0.co;2-b. View

Agnese D, Abdessalam S, Burak Jr W, Magro C, Pozderac R, Walker M . Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003; 134(4):542-7. DOI: 10.1016/s0039-6060(03)00275-7. View

Bafaloukos D, Gogas H . The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004; 30(6):515-20. DOI: 10.1016/j.ctrv.2004.05.001. View

Bottoni U, Clerico R, Paolino G, Ambrifi M, Corsetti P, Calvieri S . Predictors and survival in patients with melanoma brain metastases. Med Oncol. 2013; 30(1):466. DOI: 10.1007/s12032-013-0466-2. View

Jensen I, Zacherle E, Blanchette C, Zhang J, Yin W . Evaluating cost benefits of combination therapies for advanced melanoma. Drugs Context. 2016; 5:212297. PMC: 4974051. DOI: 10.7573/dic.212297. View

Hillner B, Agarwala S, Middleton M . Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. J Clin Oncol. 2000; 18(7):1474-80. DOI: 10.1200/JCO.2000.18.7.1474. View

Meng Y, Hertel N, Ellis J, Morais E, Johnson H, Philips Z . The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. Eur J Health Econ. 2018; 19(8):1163-1172. DOI: 10.1007/s10198-018-0964-4. View

Lin D, Feuer E, Etzioni R, Wax Y . Estimating medical costs from incomplete follow-up data. Biometrics. 1997; 53(2):419-34. View

Elliott T, Whiteman D, Olsen C, Gordon L . Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis. Appl Health Econ Health Policy. 2017; 15(6):805-816. DOI: 10.1007/s40258-017-0341-y. View

10.

Tran A, Fogarty G, Nowak A, Diaby V, Hong A, Watts C . Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases. Appl Health Econ Health Policy. 2020; 18(5):679-687. DOI: 10.1007/s40258-020-00560-1. View

11.

Hofmann U, Szedlak M, Rittgen W, JUNG E, Schadendorf D . Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002; 87(2):151-7. PMC: 2376106. DOI: 10.1038/sj.bjc.6600428. View

12.

Baker M, Kessler L, Urban N, Smucker R . Estimating the treatment costs of breast and lung cancer. Med Care. 1991; 29(1):40-9. DOI: 10.1097/00005650-199101000-00004. View

13.

Crott R, Ali F, Burdette-Radoux S . Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health. 2004; 7(4):423-32. DOI: 10.1111/j.1524-4733.2004.74005.x. View

14.

Lo S, Hong A, Haydu L, Ahmed T, Paton E, Steel V . Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. Trials. 2019; 20(1):477. PMC: 6683544. DOI: 10.1186/s13063-019-3555-5. View

15.

Hong A, Fogarty G, Dolven-Jacobsen K, Burmeister B, Lo S, Haydu L . Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019; 37(33):3132-3141. DOI: 10.1200/JCO.19.01414. View

16.

Deckers E, Hoekstra-Weebers J, Damude S, Francken A, Ter Meulen S, Bastiaannet E . The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB-IIC Patients-Results After 3 Years. Ann Surg Oncol. 2019; 27(5):1407-1417. PMC: 7138761. DOI: 10.1245/s10434-019-07825-7. View

17.

Brown P, Jaeckle K, Ballman K, Farace E, Cerhan J, Anderson S . Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016; 316(4):401-409. PMC: 5313044. DOI: 10.1001/jama.2016.9839. View

18.

Chukwueke U, Batchelor T, Brastianos P . Management of Brain Metastases in Patients With Melanoma. J Oncol Pract. 2016; 12(6):536-42. DOI: 10.1200/JOP.2016.011882. View

19.

Fogarty G, Morton R, Vardy J, Nowak A, Mandel C, Forder P . Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial. BMC Cancer. 2011; 11:142. PMC: 3107806. DOI: 10.1186/1471-2407-11-142. View